Dupilumab: A Review of Present Indications and Off-Label Uses

• Published in: Journal of investigational allergology & clinical immunology Vol. 32; no. 2; pp. 97 - 115
• Main Authors: Muñoz-Bellido, F J, Moreno, E, Dávila, I
• Format: Journal Article
• Language: English
• Published: Spain Esmon Publicidad 01.01.2022
• Subjects: Allergic bronchopulmonary aspergillosis; Allergic rhinitis; Alopecia; Antibodies, Monoclonal, Humanized - therapeutic use; Aspergillosis; Bullous pemphigoid; Clinical trials; Contact dermatitis; Eczema; Eczema - drug therapy; Esophagitis; Food allergies; Gastrointestinal diseases; Humans; Inflammation; Interleukin 13; Interleukin 4; Leukocytes (eosinophilic); Monoclonal antibodies; Netherton syndrome; Off-Label Use; Respiratory diseases; Skin diseases; Urticaria; Food allergy; Allergic contact dermatitis; Cutaneous autoimmune bullous diseases; Eosinophilic esophagitis; Allergic bronchopulmonary aspergillosis; Chronic urticaria; Dupilumab; Alopecia areata

Recent advances in our understanding of T2 inflammation have revealed more diseases in which T2 inflammation is involved. Dupilumab is a recently developed monoclonal antibody that blocks signaling of IL-4 and IL-13, both of which are crucial cytokines in the T2 response. New possible indications ar...